Topics Archives: Solid Tumor Targets

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, innovative therapies targeting CCR8 showed a strong surge. LM-108 from LaiSun Pharma/China National Biotec Group and ICP-B05 from Innocare demonstrated promising efficacy, with significant depletion of tumor-infiltrating Treg cells. Meanwhile, major pharmaceutical companies including Bristol Myers Squibb, Agenus, Gilead, and Jounce have made substantial investments in CCR8 programs, highlighting the strategic importance of CCR8 as a key target for overcoming resistance to PD-1/L1 therapies.

STAB1 (Stabilin-1) is an emerging immunoregulatory receptor expressed on tumor-associated macrophages. Targeting STAB1-driven macrophage reprogramming offers a promising strategy to reverse tumor immune suppression and enhance cancer immunotherapy responses within the tumor microenvironment.

Over the past year, Cadherin-3 (CDH3, P-cadherin), traditionally regarded as a classical cell-cell adhesion molecule, has increasingly attracted attention in oncology drug development and international scientific conferences. Early clinical data from CDH3-targeted antibody drug conjugates (ADCs) in solid tumors, particularly non-small cell lung cancer (NSCLC), have demonstrated promising objective response signals, drawing significant interest from both academia and the biopharmaceutical industry. In parallel, bispecific antibodies and T cell redirection strategies targeting CDH3 have entered early clinical or translational exploration. Collectively, these advances suggest that CDH3 is transitioning from a tumor-associated marker to a therapeutically actionable cancer target with translational potential.

Cadherin-17 (CDH17) is a non-classical calcium-dependent adhesion protein predominantly expressed in the intestinal epithelium and highly upregulated in multiple gastrointestinal tumors. Due to its tumor-specific expression, CDH17 has become a promising therapeutic target. Current CDH17-targeting strategies include: Antibody-drug conjugates (ADC), Cell therapies (CAR-T/CAR-NK), Monoclonal, bispecific, or trispecific antibodies.